CoChat
Sign Up
Cited by 215

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Recent advances in MMP inhibitor design

Fisher, Jed F., Mobashery, Shahriar·2006·Cancer and Metastasis Reviews
DOI 10.1007/s10555-006-7894-9
Open this paper in CoChat — free account

Abstract

The search for an MMP inhibitor with anticancer efficacy is a nearly three-decade endeavor. This inhibitor is yet to be found. The reasons for this failure include shortcomings in the chemistry of these compounds (including broad MMP sub-type selectivity, metabolic lability, and toxicity) as well as the emerging, and arguably extraordinary, complexity of MMP cell (and cancer) biology. Together these suggest that the successful anticancer inhibitor must possess MMP selectivity against the MMP subtype whose involvement is critical, yet highly temporally (with respect to metastatic progression) and mechanistically (with respect to matrix degradation) regulated. This review summarizes the progression of chemical structure and mechanistic thinking toward these objectives, with emphasis on the disappointment, the perseverance, and the resilient optimism that such an inhibitor is there to be discovered.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10555-006-7894-9

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • As a hydroxamic acid-based MMP inhibitor, Ro 28-2653 may also display lower binding affinity for other MMPs, as well as for ADAM and ADAMTS metalloproteinases.

    “As a hydroxamic acid-based MMP inhibitor, it may also display lower binding affinity for other MMPs, as well as for ADAM and A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS) metalloproteinases31–35.”

    From MT1-MMP inhibition rejuvenates ageing brain and rescues cognitive deficits in obesity (2025) · cites this paper as [35]

  • Ro 28-2653 is an orally available, brain-penetrant inhibitor with high specificity for MT1-MMP, MMP2, and MMP9.

    “Ro 28-2653 is an orally available, brain-penetrant inhibitor with high specificity for MT1-MMP, MMP2, and MMP9.”

    From MT1-MMP inhibition rejuvenates ageing brain and rescues cognitive deficits in obesity (2025) · cites this paper as [35]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 221

  1. Breuer E, Frant J, Reich R: Recent non-hydroxamate matrix metalloproteinase inhibitors. Expert Opin Ther Patents 15: 253–269, 2005 · DOI
  2. Hodgson J: Remodelling MMPIs. Biotechnology 13: 554–557, 1995
  3. Ramnath N, Creaven PJ: Matrix metalloproteinase inhibitors. Curr Oncol Rep 6: 96–102, 2004 · DOI
  4. Handsley MM, Edwards DR: Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 115: 849–860, 2005 · DOI
  5. Wallach J, Hornebeck W: Matrix metalloproteases and cancer. Novel perspectives in the role and control of matrix metalloproteinases in tumor progression. Biochimie 87: 241, 2005 · DOI
  6. Bjorklund M, Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta (Rev. Cancer) 1755: 37–69, 2005
  7. Demers M, Couillard J, Belanger S, St-Pierre Y: New roles for matrix metalloproteinases in metastasis. Crit Rev Immunol 25: 493–523, 2005 · DOI
  8. Fingleton B: Matrix metalloproteinases: Roles in cancer and metastasis. Front Biosci 11: 479–491, 2006 · DOI
  9. Matter H, Schudok M: Recent advances in the design of matrix metalloprotease inhibitors. Curr Opin Drug Discov Devel 7: 513–535, 2004
  10. Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, Matziari M, Yiotakis A, Dive V: Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 87: 393–402, 2005 · DOI
  11. Jani M, Tordai H, Trexler M, Banyai L, Patthy L: Hydroxamate-based peptide inhibitors of matrix metalloprotease 2. Biochimie 87: 385–392, 2005 · DOI
  12. Kontogiorgis CA, Papaioannou P, Hadjipavlou-Litina DJ: Matrix metalloproteinase inhibitors: A review on pharmacophore mapping and (Q)SARs results. Curr Med Chem 12: 339–355, 2005 · DOI
  13. Mannello F, Tonti G, Papa S: Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 5: 285–298, 2005 · DOI
  14. Maskos K: Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 87: 249–263, 2005 · DOI
  15. Rao BG: Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 11: 295–322, 2005 · DOI
  16. Tyndall JD, Nall T, Fairlie DP: Proteases universally recognize beta strands in their active sites. Chem Rev 105: 973–999, 2005 · DOI
  17. Vihinen P, Ala-aho R, Kahari VM: Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5: 203–220, 2005 · DOI
  18. Wasserman ZR: Making a new turn in matrix metalloprotease inhibition. Chem Biol 12: 143–144, 2005 · DOI
  19. Pender SL, MacDonald TT: Matrix metalloproteinases and the gut—new roles for old enzymes. Curr Opin Pharmacol 4: 546–550, 2004 · DOI
  20. Jian Liu K, Rosenberg GA: Matrix metalloproteinases and free radicals in cerebral ischemia. Free Rad Biol Med 39: 71–80, 2005 · DOI
  21. Yong VW: Metalloproteinases: Mediators of Pathology and Regeneration in the CNS. Nat Rev Neurosci 6: 931–944, 2005 · DOI · Paper page
  22. Tayebjee MH, Lip GY, MacFadyen RJ: Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Curr Med Chem 12: 917–925, 2005 · DOI
  23. Demedts IK, Brusselle GG, Bracke KR, Vermaelen KY, Pauwels RA: Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol 5: 257–263, 2005 · DOI
  24. Naito Y, Yoshikawa T: Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 26: 379–390, 2005 · DOI
  25. McIntyre JO, Fingleton B, Wells KS, Piston DW, Lynch CC, Gautam S, Matrisian LM: Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J 377: 617–628, 2004 · DOI
  26. Fingleton B, Menon R, Carter KJ, Overstreet PD, Hachey DL, Matrisian LM, McIntyre JO: Proteinase activity in human and murine saliva as a biomarker for proteinase inhibitor efficacy. Clin Cancer Res 10: 7865–7874, 2004 · DOI
  27. Gerlach RF, Tanus-Santos JE, Vihinen P: Circulating matrix metalloproteinase-9 levels as a biomarker of disease. Clin Cancer Res 11: 8887–8888, 2005 · DOI
  28. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J: The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11: 7967–7985, 2005 · DOI
  29. Rosenberg GA: Matrix metalloproteinases biomarkers in multiple sclerosis. Lancet 365: 1291–1293, 2005 · DOI
  30. Sledge GWJ: Transforming technologies and breast cancer. Clin Breast Cancer 6: 283, 2005 · DOI
  31. Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J, Somiari RI: Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett. 233: 98–107, 2006 · DOI
  32. Rothenberg ML, Carbone DP, Johnson DH: Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 3: 303–309, 2003 · DOI
  33. Millar AW, Lynch KP: Rethinking clinical trials for cytostatic drugs. Nat Rev Cancer 3: 540–545, 2003 · DOI
  34. Parulekar WR, Eisenhauer EA: Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. J Natl Cancer Inst 96: 990–997, 2004 · DOI
  35. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE: Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 22: 4683–4690, 2004 · DOI
  36. Goffin JR, Anderson IC, Supko JG, Eder JPJ, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT: Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 11: 3417–3424, 2005 · DOI
  37. Jones PH, Christodoulos K, Dobbs N, Thavasu P, Balkwill F, Blann AD, Caine GJ, Kumar S, Kakkar AJ, Gompertz N, Talbot DC, Ganesan TS, Harris AL: Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. Br J Cancer 91: 30–36, 2004 · DOI
  38. Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA: Marimastat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized, double-blind, phase I/II trial. Clin Cancer Res 11: 4437–4443, 2005 · DOI
  39. Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML: Pyran-containing sulfonamide hydroxamic acids: Potent MMP inhibitors that spare MMP-1. Bioorg Med Chem Lett 14: 3389–3395, 2004 · DOI
  40. Zask A, Kaplan J, Du X, MacEwan G, Sandanayaka V, Eudy N, Levin J, Jin G, Xu J, Cummons T, Barone D, Ayral-Kaloustian S, Skotnicki J: Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors. Bioorg Med Chem Lett 15: 1641–1645, 2005 · DOI
  41. Duan JJ, Lu Z, Wasserman ZR, Liu R, Covington MB, Decicco CP: Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme. Bioorg Med Chem Lett 15: 2970–2973, 2005 · DOI
  42. Wall L, Talbot DC, Bradbury P, Jodrell DI: A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB–3644 in patients with solid tumours. Br J Cancer 90: 800–804, 2004 · DOI
  43. Jozic D, Bourenkov G, Lim NH, Visse R, Nagase H, Bode W, Maskos K: X-ray structure of human proMMP-1: New insights into procollagenase activation and collagen binding. J Biol Chem 280: 9578–9585, 2005 · DOI
  44. Tsai KC, Lin TH: A ligand-based molecular modeling study on some matrix metalloproteinase-1 inhibitors using several 3D QSAR techniques. J Chem Inf Comput Sci 44: 1857–1871, 2004 · DOI
  45. Irwin JJ, Raushel FM, Shoichet BK: Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry 44: 12316–12328, 2005 · DOI
  46. Bertini I, Fragai M, Giachetti A, Luchinat C, Maletta M, Parigi G, Yeo KJ: Combining in silico tools and NMR data to validate protein-ligand structural models: Application to matrix metalloproteinases. J Med Chem 48: 7544–7559, 2005 · DOI
  47. Matter H, Schudok M, Elshorst B, Jacobs DM, Saxena K, Kogler H: QSAR-by-NMR: Quantitative insights into structural determinants for binding affinity by analysis of 1H/15N chemical shift differences in MMP-3 ligands. Bioorg Med Chem Lett 15: 1779–1783, 2005 · DOI
  48. Lukacova V, Zhang Y, Mackov M, Baricic P, Raha S, Calvo JA, Balaz S: Similarity of binding sites of human matrix metalloproteinases. J Biol Chem 279: 14194–14200, 2004 · DOI
  49. Takahashi K, Ikura M, Habashita H, Nishizaki M, Sugiura T, Yamamoto S, Nakatani S, Ogawa K, Ohno H, Nakai H, Toda M: Novel matrix metalloproteinase inhibitors: Generation of lead compounds by the in silico fragment-based approach. Bioorg Med Chem 13: 4527–4543, 2005 · DOI
  50. Khandelwal A, Lukacova V, Comez D, Kroll DM, Raha S, Balaz S: A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands. J Med Chem 48: 5437–5447, 2005 · DOI
  51. Lukacova V, Zhang Y, Kroll DM, Raha S, Comez D, Balaz S: A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: Implications for selectivity. J Med Chem 48: 2361–2370, 2005 · DOI
  52. Pirard B, Matter H: Matrix Metalloproteinase Target Family Landscape: A Chemometrical Approach to Ligand Selectivity Based on Protein Binding Site Analysis. J Med Chem 49: 51–69, 2006 · DOI
  53. Wasserman ZR, Duan JJ, Voss ME, Xue CB, Cherney RJ, Nelson DJ, Hardman KD, Decicco CP: Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling. Chem Biol 10: 215–223, 2003 · DOI
  54. Xu X, Chen Z, Wang Y, Yamada Y, Steffensen B: Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2. Biochem J 392: 127–134, 2005 · DOI
  55. Toth M, Osenkowski P, Hesek D, Brown S, Meroueh S, Sakr W, Mobashery S, Fridman R: Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. Biochem J 387: 497–506, 2005 · DOI
  56. Pelman GR, Morrison CJ, Overall CM: Pivotal molecular determinants of peptidic and collagen triple helicase activities reside in the S3' subsite of matrix metalloproteinase 8 (MMP-8): the role of hydrogen bonding potential of ASN188 and TYR189 and the connecting cis bond. J Biol Chem 280: 2370–2377, 2005 · DOI
  57. Eatock M, Cassidy J, Johnson J, Morrison R, Devlin M, Blackey R, Owen S, Choi L, Twelves C: A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 55: 39–46, 2005 · DOI
  58. Borkakoti N: Matrix metalloprotease inhibitors: Design from structure. Biochem Soc Trans 32: 17–20, 2004 · DOI
  59. Fujino H, Kondo K, Ishikura H, Maki H, Kinoshita H, Miyoshi T, Takahashi Y, Sawada N, Takizawa H, Nagao T, Sakiyama S, Monden Y: Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer. Clin Cancer Res 6: 3944–3948, 2000
  60. Hojo K, Maki H, Sawada TY, Maekawa R, Yoshioka T: Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents. Anticancer Res 22: 3253–3259, 2002
  61. Ikonomidis JS, Hendrick JW, Parkhurst AM, Herron AR, Escobar PG, Dowdy KB, Stroud RE, Hapke E, Zile M, Spinale FG: Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: Effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 288: H149–158, 2005 · DOI
  62. Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH, Khokha R: Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 97: 380–390, 2005 · DOI
  63. Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK: Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J Med Chem 45: 219–232, 2002 · DOI
  64. Wada CK: The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories. Curr Top Med Chem 4: 1255–1267, 2004 · DOI
  65. Scatena R: Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Investig Drugs 9: 2159–2165, 2000 · DOI
  66. Arlt M, Kopitz C, Pennington C, Watson KLM, Krell HW, Bode W, Gansbacher B, Khokha R, Edwards DR, Kruger A: Increase in Gelatinase-specificity of Matrix Metalloproteinase Inhibitors Correlates with Antimetastatic Efficacy in a T-Cell Lymphoma Model. Clin Cancer Res 7: 1912–1922, 2001
  67. Deryugina EI, Ratnikov BI, Strongin AY: Prinomastat, a hydroxamate inhibitor of matrix metalloproteinases, has a complex effect on migration of breast carcinoma cells. Int J Cancer 104: 533–541, 2003 · DOI
  68. Kruger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V, Harbeck N, Gansbacher B, Schmitt M: Hydroxamate—Type Matrix Metalloproteinase Inhibitor Batimastat Promotes Liver Metastasis. Cancer Res 62: 5543–5550, 2002
  69. Savinov AY, Rozanov DV, Golubkov VS, Wong FS, Strongin AY: Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas. J Biol Chem 280: 27755–27758, 2005 · DOI
  70. Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, Shalinsky DR, Shimada H, DeClerck YA, Gomer CJ: The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 64: 2328–2332, 2004 · DOI
  71. Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G: Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor. Clin Cancer Res. 10: 909–915, 2004 · DOI
  72. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA: Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23: 842–849, 2005 · DOI
  73. Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT, Campbell JA, Walker KA, Martin R, Van Wart H, Browner MF: Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 6: 217–221, 1999 · DOI
  74. Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T, Kaldjian E, Welgus H, Baragi V: Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 48: 1742–1749, 2003 · DOI
  75. Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R: Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem 46: 2361–2375, 2003 · DOI
  76. Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin J, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB: Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem 46: 2376–2396, 2003 · DOI
  77. Becker DP, Villamil CI, Barta TE, Bedell LJ, Boehm TL, Decrescenzo GA, Freskos JN, Getman DP, Hockerman S, Heintz R, Howard SC, Li M, McDonald JJ, Carron C, Funckes-Shippy CL, Mehta PP, Munie GE, Swearingen CA: Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy. J Med Chem 48: 6713–6730, 2005 · DOI
  78. Sani M, Candiani G, Pecker F, Malpezzi L, Zanda M: Novel highly potent, structurally simple [gamma]-trifluoromethyl [gamma]-sulfone hydroxamate inhibitor of stromelysin-1 (MMP-3). Tetrahedron Lett 46: 2393–2396, 2005 · DOI
  79. Rossello A, Nuti E, Carelli P, Orlandini E, Macchia M, Nencetti S, Zandomeneghi M, Balzano F, Uccello Barretta G, Albini A, Benelli R, Cercignani G, Murphy G, Balsamo A: N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorg Med Chem Lett 15: 1321–1326, 2005 · DOI
  80. Ishikawa T, Nishigaki F, Miyata S, Hirayama Y, Minoura K, Imanishi J, Neya M, Mizutani T, Imamura Y, Naritomi Y, Murai H, Ohkubo Y, Kagayama A, Mutoh S: Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. Br J Pharmacol 144: 133–143, 2005 · DOI
  81. Muraishi Y, Mitani N, Fuse H, Saiki I: Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma. Anticancer Res 21: 3845–3852, 2001
  82. Shiraga M, Yano S, Yamamoto A, Ogawa H, Goto H, Miki T, Miki K, Zhang H, Sone S: Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res 62: 5967–5973, 2002
  83. Mori T, Nakahashi K, Kyokuwa M, Yamasaki S, Nagasawa H: A matrix metalloproteinase inhibitor, ONO-4817, retards the development of mammary tumor and the progression of uterine adenomyosis in mice. Anticancer Res 22: 3985–3988, 2002
  84. Yamamoto A, Yano S, Shiraga M, Ogawa H, Goto H, Miki T, Zhang H, Sone S: A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int J Cancer 103: 822–828, 2003 · DOI
  85. Yamashita T, Fujii M, Tomita T, Ishiguro R, Tashiro M, Tokumaru Y, Imanishi Y, Kanke M, Ogawa K, Kameyama K, Otani Y: The inhibitory effect of matrix metalloproteinase inhibitor ONO-4817 on lymph node metastasis in tongue carcinoma. Anticancer Res 23: 2297–2302, 2003
  86. Yamada A, Uegaki A, Nakamura T, Ogawa K: ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res 49: 144–146, 2000 · DOI
  87. Masuda T, Nakayama Y: Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty. J Med Chem 46: 3497–3501, 2003 · DOI
  88. Yoshioka M, Yokoyama N, Masuda K, Honna T, Hinode D, Nakamura R, Rouabhia M, Mayrand D, Grenier D: Effect of hydroxamic acid-based matrix metalloproteinase inhibitors on human gingival cells and Porphyromonas gingivalis. J Periodontol 74: 1219–1224, 2003 · DOI
  89. Matsuno H, Ishisaki A, Nakajima K, Kozawa O: Effect of a synthetic matrix metalloproteinase inhibitor (ONO-4817) on neointima formation in hypercholesterolemic hamsters. J Cardiovasc Pharmacol 44: 57–65, 2004 · DOI
  90. Naito Y, Takagi T, Kuroda M, Katada K, Ichikawa H, Kokura S, Yoshida N, Okanoue T, Yoshikawa T: An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm Res 53: 462–468, 2004 · DOI
  91. Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS: Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates. Bioorg Med Chem Lett 15: 4345–4349, 2005 · DOI
  92. Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, Brennan F, Cummons T, Clarke D, Vansell N, Nickerson-Nutter C, Barone D, Mohler K, Black R, Skotnicki J, Gibbons J, Feldmann M, Frost P, Larsen G, Lin LL: Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpho linecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther 309: 348–355, 2004 · DOI
  93. Zhang Y, Hegen M, Xu J, Keith JC, Jin G, Du X, Cummons T, Sheppard BJ, Sun L, Zhu Y, Rao V, Wang Q, Xu W, Cowling R, Nickerson-Nutter CL, Gibbons J, Skotnicki J, Lin LL, Levin J: Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme. Int Immunopharmacol 4: 1845–1857, 2004 · DOI
  94. Cherney RJ, Mo R, Meyer DT, Hardman KD, Liu R, Covington MB, Qian M, Wasserman ZR, Christ DD, Trzaskos JM, Newton RC, Decicco CP: Sultam hydroxamates as novel matrix metalloproteinase inhibitors. J Med Chem 47: 2981–2983, 2004 · DOI
  95. Cherney RJ, King BW, Gilmore JL, Liu R, Covington MB, Duan JJ, Decicco CP: Conversion of potent MMP inhibitors into selective TACE inhibitors. Bioorg Med Chem Lett 16: 1028–1031, 2006 · DOI
  96. Kocer SS, Walker SG, Zerler B, Golub LM, Simon SR: Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines, and ilomastat block Bacillus anthracis lethal factor activity in viable cells. Infect Immun 73: 7548–7557, 2005 · DOI
  97. Shoop W, Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny J, Felcetto T, Michael B, Bansal A, Cummings R, Cunningham B, Friedlander A, Douglas C, Patel S, Wisniewski D, Scapin G, Salowe S, Zaller D, Chapman K, Scolnick E, Schmatz D, Bartizal K, MacCoss M, Hermes J: Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A 102: 7958–7963, 2005 · DOI
  98. Johnson SL, Jung D, Forino M, Chen Y, Satterthwait A, Rozanov DV, Strongin AY, Pellecchia M: Anthrax Lethal Factor Protease Inhibitors: Synthesis, SAR, and Structure–Based 3D QSAR Studies. J Med Chem 49: 27–30, 2006 · DOI
  99. Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny J, Tang W, Bansal A, Cummings R, Cunningham B, Friedlander A, Douglas C, Salowe S, Zaller D, Scolnick E, Schmatz D, Bartizal K, Hermes J, Maccoss M, Chapman K: The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett 16: 964–968, 2006 · DOI
  100. Hu Y, Xiang JS, DiGrandi MJ, Du X, Ipek M, Laakso LM, Li J, Li W, Rush TS, Schmid J, Skotnicki JS, Tam S, Thomason JR, Wang Q, Levin JI: Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem 13: 6629–6644, 2005 · DOI
  101. Xiang JS, Hu Y, Rush TS, Thomason JR, Ipek M, Sum PE, Abrous L, Sabatini JJ, Georgiadis K, Reifenberg E, Majumdar M, Morris EA, Tam S: Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg Med Chem Lett 16: 311–316, 2006 · DOI
  102. Ma D, Jiang Y, Chen F, Gong L, Ding K, Xu Y, Wang R, Ge A, Ren J, Li J, Li J, Ye Q: Selective inhibition of MMP isozymes and In vivo Protection against Emphysema by Substituted gamma-Keto Carboxylate. J Med Chem 49: 456–458, 2006 · DOI
  103. Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA, Trail PA: Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 61: 8480–8485, 2001
  104. Borg TK: It's the matrix! ECM, proteases, and cancer. Am J Pathol 164: 1141–1142, 2004 · DOI
  105. Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC: An introduction to matrikines: Extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Crit Rev Oncol Hematol 49: 199–202, 2004 · DOI
  106. Radisky DC, Bissell MJ: Cancer. Respect thy neighbor! Science 303: 775–777, 2004 · DOI
  107. Yamaguchi H, Wyckoff J, Condeelis J: Cell migration in tumors. Curr Opin Cell Biol 17: 559–564, 2005 · DOI
  108. Zigrino P, Loffek S, Mauch C: Tumor-stroma interactions: Their role in the control of tumor cell invasion. Biochimie 87: 321–328, 2005 · DOI
  109. Maquart FX, Bellon G, Pasco S, Monboisse JC: Matrikines in the regulation of extracellular matrix degradation. Biochimie 87: 353–360, 2005 · DOI
  110. Comoglio PM, Trusolino L: Cancer: The matrix is now in control. Nat Med 11: 1156–1159, 2005 · DOI
  111. Steeg PS: New insights into the tumor metastatic process revealed by gene expression profiling. Am J Pathol 166: 1291–1294, 2005 · DOI
  112. Steeg PS: Cancer biology: Emissaries set up new sites. Nature 438: 750–751, 2005 · DOI
  113. Clamp AR, Jayson GC: The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer 93: 967–972, 2005 · DOI
  114. Zatovicova M, Sedlakova O, Svastova E, Ohradanova A, Ciampor F, Arribas J, Pastorek J, Pastorekova S: Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 93: 1267–1276, 2005 · DOI
  115. Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol 1: 119–150, 2006 · DOI
  116. Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H: A phase I study of oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer. Clin Cancer Res 10: 1963–1970, 2004 · DOI
  117. Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW: A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 10: 1971–1975, 2004 · DOI
  118. Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA: Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23: 2831–2839, 2005 · DOI
  119. Gatto C, Rieppi M, Borsotti P, Innocenti S, Ceruti R, Drudis T, Scanziani E, Casazza AM, Taraboletti G, Giavazzi R: BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 5: 3603–3607, 1999
  120. Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, Sorensen JM, Kumor K, Kennedy S, Grochow LB: Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 48: 269–274, 2001 · DOI
  121. Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR: A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs 16: 997–1002, 2005 · DOI
  122. Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Stafford S, Waterfield B, Matthews S, Lathia C, Schwartz B, Agarwal V, Humphrey R, Seymour AL: An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Invest New Drugs 23: 437–443, 2005 · DOI
  123. Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L: An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Invest New Drugs 23: 63–71, 2005 · DOI
  124. Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heemann U: Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 79: 655–661, 2005 · DOI
  125. Mannello F, Tonti GA, Bagnara GP, Papa S: Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 24: In press, 2006 · DOI
  126. Hurst DR, Schwartz MA, Jin Y, Ghaffari MA, Kozarekar P, Cao J, Sang QX: Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors. Biochem J 392: 527–536, 2005 · DOI
  127. Fragai M, Nativi C, Richichi B, Venturi C: Design In silico, Synthesis and Binding Evaluation of a Carbohydrate-based Scaffold for Structurally Novel Inhibiitors of MMPs. ChemBioChem 6: 1345–1349, 2005 · DOI
  128. Lee M, Bernardo MM, Meroueh SO, Brown S, Fridman R, Mobashery S: Synthesis of chiral 2-(4-phenoxy phenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org Lett 7: 4463–4465, 2005 · DOI
  129. Parker MH, Ortwine DF, O'Brien PM, Lunney EA, Banotai CA, Mueller WT, McConnell P, Brouillette CG: Stereoselective binding of an enantiomeric pair of stromelysin-1 inhibitors caused by conformational entropy factors. Bioorg Med Chem Lett 10: 2427–2430, 2000 · DOI
  130. O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H: Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem 43: 156–166, 2000 · DOI
  131. Pochetti G, Gavuzzo E, Campestre C, Agamennone M, Tortorella P, Consalvi V, Gallina C, Hiller O, Tschesche H, Tucker PA, Mazza F: Structural Insight into the Stereoselective Inhibition of MMP-8 by Enantiomeric Sulfonamide Phosphonates. J Med Chem 49: 923–931, 2006 · DOI
  132. Ikejiri M, Bernardo MM, Meroueh SO, Brown S, Chang M, Fridman R, Mobashery S: Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 70: 5709–5712, 2005 · DOI
  133. Ikejiri M, Bernardo MM, Bonfil RD, Toth M, Chang M, Fridman R, Mobashery S: Potent Mechanism-based Inhibitors for Matrix Metalloproteinases. J Biol Chem 280: 33992–34002, 2005 · DOI
  134. Solomon A, Rosenblum G, Gonzales PE, Leonard JD, Mobashery S, Milla ME, Sagi I: Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity. J Biol Chem 279: 31646–31654, 2004 · DOI
  135. Kruger A, Arlt MJ, Gerg M, Kopitz C, Bernardo MM, Chang M, Mobashery S, Fridman R: Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 65: 3523–3526, 2005 · DOI
  136. Bonfil RD, Sabbota A, Nabha S, Bernardo MM, Dong Z, Meng H, Yamamoto H, Chinni SR, Lim I, Chang M, Filetti LC, Mobashery S, Cher ML, Fridman R: Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer 118: 2721–2726, 2006 · DOI
  137. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Lipton SA: A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 25: 6401–6408, 2005 · DOI
  138. Grams F, Brandstetter H, D'Alo S, Geppert D, Krell HW, Leinert H, Livi V, Menta E, Oliva A, Zimmermann G: Pyrimidine-2,4,6-Triones: A new effective and selective class of matrix metalloproteinase inhibitors. Biol Chem 382: 1277–1285, 2001 · DOI
  139. Genter MB, Warner BM, Krell HW, Bolon B: Reduction of alachlor-induced olfactory mucosal neoplasms by the matrix metalloproteinase inhibitor Ro 28-2653. Toxicol Pathol 33: 593–599, 2005 · DOI · Paper page
  140. Lein M, Jung K, Ortel B, Stephan C, Rothaug W, Juchem R, Johannsen M, Deger S, Schnorr D, Loening S, Krell HW: The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 21: 2089–2096, 2002 · DOI
  141. Mangoldt D, Sinn B, Lein M, Krell HW, Schnorr D, Loening SA, Jung K: The novel synthetic inhibitor of matrix metalloproteinases Ro 28–2653 induces apoptosis in Dunning tumor cells. Apoptosis 7: 217–220, 2002 · DOI
  142. Jung K, Krell HW, Ortel B, Hasan T, Romer A, Schnorr D, Loening SA, Lein M: Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats. Prostate 54: 206–211, 2003 · DOI
  143. Maquoi E, Sounni NE, Devy L, Olivier F, Frankenne F, Krell HW, Grams F, Foidart JM, Noel A: Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 10: 4038–4047, 2004 · DOI
  144. Kruse MN, Becker C, Lottaz D, Kohler D, Yiallouros I, Krell HW, Sterchi EE, Stocker W: Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J 378: 383–389, 2004 · DOI
  145. Demeulemeester D, Collen D, Lijnen HR: Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem Biophys Res Commun 329: 105–110, 2005 · DOI
  146. Brandstetter H, Grams F, Glitz D, Lang A, Huber R, Bode W, Krell HW, Engh RA: The 1.8-A Crystal Structure of a Matrix Metalloproteinase 8-Barbiturate Inhibitor Complex Reveals a Previously Unobserved Mechanism for Collagenase Substrate Recognition. J Biol Chem 276: 17405–17412, 2001 · DOI
  147. Bertini I, Calderone V, Cosenza M, Fragai M, Lee YM, Luchinat C, Mangani S, Terni B, Turano P: Conformational variability of matrix metalloproteinases: Beyond a single 3D structure. Proc Natl Acad Sci USA 102: 5334–5339, 2005 · DOI
  148. Engel CK, Pirard B, Schimanski S, Kirsch R, Habermann J, Klingler O, Schlotte V, Weithmann KU, Wendt KU: Structural Basis for the Highly Selective Inhibition of MMP-13. Chem Biol 12: 181–189, 2005 · DOI
  149. Kim SH, Pudzianowski AT, Leavitt KJ, Barbosa J, McDonnell PA, Metzler WJ, Rankin BM, Liu R, Vaccaro W, Pitts W: Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett 15: 1101–1106, 2005 · DOI
  150. Dunten P, Kammlott U, Crowther R, Levin W, Foley LH, Wang P, Palermo R: X-ray structure of a novel MMP inhibitor complexed to stromelysin. Protein Sci 10: 923–926, 2001 · DOI
  151. Blagg JA, Noe MC, Wolf-Gouveia LA, Reiter LA, Laird ER, Chang SP, Danley DE, Downs JT, Elliott NC, Eskra JD, Griffiths RJ, Hardink JR, Haugeto AI, Jones CS, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robinson RP, Subramanyam C, Vaughn-Bowser ML, Yocum SA: Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 15: 1807–1810, 2005 · DOI
  152. Breyholz HJ, Schafers M, Wagner S, Holtke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K: C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging. J Med Chem 48: 3400–3409, 2005 · DOI
  153. Kopka K, Breyholz HJ, Wagner S, Law MP, Riemann B, Schroer S, Trub M, Guilbert B, Levkau B, Schober O, Schafers M: Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl Med Biol 31: 257–267, 2004 · DOI
  154. Schafers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schafers KP, Law M, Schober O, Levkau B: Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 109: 2554–2559, 2004 · DOI
  155. Anonymous: MMP-13 Inhibitors. Aventis Res. & Tech. WO2004060874 & WO2004060883. Expert Opin Ther Patents 15: 237–241, 2005 · DOI
  156. Puerta DT, Mongan J, Tran BL, McCammon JA, Cohen SM: Potent, selective pyrone-based inhibitors of stromelysin-1. J Am Chem Soc 127: 14148–14149, 2005 · DOI
  157. Puerta DT, Morgan J, Tran BL, McCammon JA, Cohen SM: From Model Complexes to Metalloprotein Inhibition: A Synergistic Approach to Structure-Based Drug Discovery. Angew Chem Int Ed 42: 3772–3775, 2003 · DOI
  158. He H, Puerta DT, Cohen SM, Rodgers KR: Structural and spectroscopic study of reactions between chelating zinc-binding groups and mimics of the matrix metalloproteinase and disintegrin metalloprotease catalytic sites: the coordination chemistry of metalloprotease inhibition. Inorg Chem 44: 7431–7442, 2005 · DOI
  159. Onaran MB, Comeau AB, Seto CT: Squaric acid-based peptidic inhibitors of MMP-1. J Org Chem 70: 10792–10802, 2005 · DOI
  160. Juers DH, Kim J, Matthews BW, Sieburth SM: Structural Analysis of Silanediols as Transition-State-Analogue Inhibitors of the Benchmark Metalloprotease Thermolysin. Biochemistry 44: 16524–16528, 2005 · DOI
  161. Sieburth SM, Chen CA: Silanediol Protease Inhibitors: From Conception to Validation. Eur J Org Chem: 311–322, 2006 · DOI
  162. Dive V, Georgiadis D, Matziari M, Makaritis A, Beau F, Cuniasse P, Yiotakis A: Phosphinic peptides as zinc metalloproteinase inhibitors. Cell Mol Life Sci 61: 2010–2019, 2004 · DOI
  163. Reiter LA, Mitchell PG, Martinelli GJ, Lopresti-Morrow LL, Yocum SA, Eskra JD: Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorg Med Chem Lett 13: 2331–2336, 2003 · DOI
  164. Gall AL, Ruff M, Kannan R, Cuniasse P, Yiotakis A, Dive V, Rio MC, Basset P, Moras D: Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. J Mol Biol 307: 577–586, 2001 · DOI
  165. Matziari M, Beau F, Cuniasse P, Dive V, Yiotakis A: Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. J Med Chem 47: 325–336, 2004 · DOI
  166. Dive V, Andarawewa KL, Boulay A, Matziari M, Beau F, Guerin E, Rousseau B, Yiotakis A, Rio MC: Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases. Int J Cancer 113: 775–781, 2005 · DOI
  167. Andarawewa KL, Motrescu ER, Chenard MP, Gansmuller A, Stoll I, Tomasetto C, Rio MC: Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res 65: 10862–10871, 2005 · DOI
  168. Andarawewa KL, Boulay A, Masson R, Mathelin C, Stoll I, Tomasetto C, Chenard MP, Gintz M, Bellocq JP, Rio M: Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res 63: 5844–5849, 2003
  169. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295: 2387–2392, 2002 · DOI · Paper page
  170. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L, Padarathsingh M: Proteases, extracellular matrix, and cancer: A workshop of the path B study section. Am J Pathol 164: 1131–1139, 2004 · DOI
  171. Breuer E, Katz Y, Hadar R, Reich R: Carbamoylphosphonate MMP inhibitors. Part 4: The influence of chirality and geometrical isomerism on the potency and selectivity of inhibition. Tetrahedron: Asymmetry 15: 2415, 2004 · DOI
  172. Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Roschenthaler GV, Hadar R, Reich R: Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. J Med Chem 47: 2826–2832, 2004 · DOI
  173. Agamennone M, Campestre C, Preziuso S, Consalvi V, Crucianelli M, Mazza F, Politi V, Ragno R, Tortorella P, Gallina C: Synthesis and evaluation of new tripeptide phosphonate inhibitors of MMP-8 and MMP-2. Eur J Med Chem 40: 271–279, 2005 · DOI
  174. Bianchini G, Aschi M, Cavicchio G, Crucianelli M, Preziuso S, Gallina C, Nastari A, Gavuzzo E, Mazza F: Design, modelling, synthesis and biological evaluation of peptidomimetic phosphinates as inhibitors of matrix metalloproteinases MMP-2 and MMP-8. Bioorg Med Chem 13: 4740–4749, 2005 · DOI
  175. Clezardin P, Fournier P, Boissier S, Peyruchaud O: In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 10: 173–180, 2003 · DOI
  176. Conte P, Coleman R: Bisphosphonates in the treatment of skeletal metastases. Semin Oncol 31: 59–63, 2004 · DOI
  177. Perry CM, Figgitt DP: Zoledronic acid: A review of its use in patients with advanced cancer. Drugs 64: 1197–1211, 2004 · DOI
  178. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100: 2613–2621, 2004 · DOI · Paper page
  179. Saba N, Khuri F: The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. Oncology 68: 10–17, 2005 · DOI
  180. Ural AU, Avcu F: Evolving therapeutic role of bisphosphonates in multiple myeloma. Br J Cancer 93: 267–268; author reply 269, 2005 · DOI
  181. Clezardin P, Ebetino FH, Fournier PG: Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity. Cancer Res 65: 4971–4974, 2005 · DOI
  182. Clezardin P: Anti-tumour activity of zoledronic acid. Cancer Treat Rev 31 Suppl 3: 1–8, 2005 · DOI
  183. Coleman RE: Bisphosphonates in breast cancer. Ann Oncol 16: 687–695, 2005 · DOI
  184. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949–2954, 2000
  185. Heikkila P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, Maisi P, van der Pluijm G, Bartlett JD, Salo T, Sorsa T: Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP–13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13: 245–254, 2002 · DOI
  186. Heikkila P, Teronen O, Hirn MY, Sorsa T, Tervahartiala T, Salo T, Konttinen YT, Halttunen T, Moilanen M, Hanemaaijer R, Laitinen M: Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. J Surg Res 111: 45–52, 2003 · DOI
  187. Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M, Rusconi C, Varettoni M, Lazzarino M: Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 104: 118–125, 2005 · DOI
  188. Corso A, Ferretti E, Lazzarino M: Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology 10: 215–224, 2005 · DOI
  189. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D'Agosto G, Bordignon V, Trento E, Cognetti F: Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69: 35–43, 2005 · DOI
  190. Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623–633, 2004 · DOI · Paper page
  191. Fingleton B: CMT-3. CollaGenex. Curr Opin Investig Drugs 4: 1460–1467, 2003
  192. Acharya MR, Venitz J, Figg WD, Sparreboom A: Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat 7: 195–208, 2004 · DOI
  193. Kivela-Rajamaki M, Maisi P, Srinivas R, Tervahartiala T, Teronen O, Husa V, Salo T, Sorsa T: Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid. J Periodontal Res 38: 583–590, 2003 · DOI
  194. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M: Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 17: 359–366, 2004 · DOI · Paper page
  195. Diguet E, Gross CE, Tison F, Bezard E: Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Exp Neurol 189: 1–4, 2004 · DOI
  196. Domercq M, Matute C: Neuroprotection by tetracyclines. Trends Pharmacol Sci 25: 609–612, 2004 · DOI
  197. Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, Tarwater P, Clements J, Barber S: Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293: 2003–2011, 2005 · DOI
  198. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W: Minocycline as a neuroprotective agent. Neuroscientist 11: 308–322, 2005 · DOI
  199. Garcia RA, Pantazatos DP, Gessner CR, Go KV, Woods VL, Villarreal FJ: Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol 67: 1128–1136, 2005 · DOI
  200. Gu Y, Lee HM, Golub LM, Sorsa T, Konttinen YT, Simon S: Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Ann Med 37: 450–460, 2005 · DOI

200 of 221 shown

Cited by

Sorted by citations

Metadata

Authors
Fisher, J. F., & Mobashery, S.
Venue
Cancer and Metastasis Reviews
Publisher
Springer Science and Business Media LLC
Published
2006-03
Volume
25
Issue
1
Pages
115-136
ISSN
  • 0167-7659
  • 1573-7233
DOI
10.1007/s10555-006-7894-9
Cited by
215
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review